Does the media favor JAZZ or AXSM?

In the previous week, Jazz Pharmaceuticals had 8 more articles in the media than Axsome Therapeutics. MarketBeat recorded 20 mentions for Jazz Pharmaceuticals and 12 mentions for Axsome Therapeutics. Jazz Pharmaceuticals' average media sentiment score of 1.42 beat Axsome Therapeutics' score of 1.29 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 17 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer JAZZ or RPRX?

In the previous week, Jazz Pharmaceuticals had 3 more articles in the media than Royalty Pharma. MarketBeat recorded 20 mentions for Jazz Pharmaceuticals and 17 mentions for Royalty Pharma. Jazz Pharmaceuticals' average media sentiment score of 1.42 beat Royalty Pharma's score of 1.40 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 17 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Royalty Pharma 13 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ZTS or JAZZ?

In the previous week, Zoetis had 16 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 36 mentions for Zoetis and 20 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.42 beat Zoetis' score of 1.13 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 29 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 17 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CORT or JAZZ?

In the previous week, Corcept Therapeutics had 13 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 33 mentions for Corcept Therapeutics and 20 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.42 beat Corcept Therapeutics' score of 0.72 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 12 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 17 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor JAZZ or SUPN?

In the previous week, Jazz Pharmaceuticals had 8 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 20 mentions for Jazz Pharmaceuticals and 12 mentions for Supernus Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.42 beat Supernus Pharmaceuticals' score of 0.99 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 17 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Supernus Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Jazz Pharmaceuticals (JAZZ) Competitors

$258.38 +2.41 (+0.94%)

Closing price 07/30/2026 04:00 PM Eastern

Extended Trading

$252.00 -6.38 (-2.47%)

As of 06:56 AM Eastern

Compare

JAZZ vs. AXSM, RPRX, ZTS, CORT, and SUPN

Should you buy Jazz Pharmaceuticals stock or one of its competitors? MarketBeat compares Jazz Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Jazz Pharmaceuticals include Axsome Therapeutics (AXSM), Royalty Pharma (RPRX), Zoetis (ZTS), Corcept Therapeutics (CORT), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "medical" sector.

How does Jazz Pharmaceuticals compare to Axsome Therapeutics?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Axsome Therapeutics (NASDAQ:AXSM) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

Jazz Pharmaceuticals has a net margin of 0.66% compared to Axsome Therapeutics' net margin of -26.59%. Jazz Pharmaceuticals' return on equity of 14.56% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	0.66%	14.56%	5.25%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Jazz Pharmaceuticals currently has a consensus price target of $259.06, indicating a potential upside of 0.26%. Axsome Therapeutics has a consensus price target of $261.48, indicating a potential upside of 11.44%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.90
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.91

In the previous week, Jazz Pharmaceuticals had 8 more articles in the media than Axsome Therapeutics. MarketBeat recorded 20 mentions for Jazz Pharmaceuticals and 12 mentions for Axsome Therapeutics. Jazz Pharmaceuticals' average media sentiment score of 1.42 beat Axsome Therapeutics' score of 1.29 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	17 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Jazz Pharmaceuticals has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 4.1% of Jazz Pharmaceuticals shares are held by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Axsome Therapeutics has lower revenue, but higher earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.80	-$356.15M	-$0.02	N/A
Axsome Therapeutics	$638.50M	18.91	-$183.17M	-$3.73	N/A

Summary

Axsome Therapeutics beats Jazz Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Royalty Pharma?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Royalty Pharma (NASDAQ:RPRX) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

Jazz Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, Royalty Pharma has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market.

Royalty Pharma has lower revenue, but higher earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.80	-$356.15M	-$0.02	N/A
Royalty Pharma	$2.44B	13.93	$770.95M	$1.47	40.15

Jazz Pharmaceuticals presently has a consensus price target of $259.06, suggesting a potential upside of 0.26%. Royalty Pharma has a consensus price target of $56.57, suggesting a potential downside of 4.15%. Given Jazz Pharmaceuticals' higher probable upside, equities research analysts clearly believe Jazz Pharmaceuticals is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.90
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 54.3% of Royalty Pharma shares are held by institutional investors. 4.1% of Jazz Pharmaceuticals shares are held by insiders. Comparatively, 18.8% of Royalty Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Royalty Pharma has a net margin of 33.88% compared to Jazz Pharmaceuticals' net margin of 0.66%. Royalty Pharma's return on equity of 29.25% beat Jazz Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	0.66%	14.56%	5.25%
Royalty Pharma	33.88%	29.25%	14.71%

In the previous week, Jazz Pharmaceuticals had 3 more articles in the media than Royalty Pharma. MarketBeat recorded 20 mentions for Jazz Pharmaceuticals and 17 mentions for Royalty Pharma. Jazz Pharmaceuticals' average media sentiment score of 1.42 beat Royalty Pharma's score of 1.40 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	17 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Royalty Pharma	13 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Royalty Pharma beats Jazz Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Zoetis?

Zoetis (NYSE:ZTS) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

92.8% of Zoetis shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 0.2% of Zoetis shares are held by insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Zoetis has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

Zoetis has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.53B	3.34	$2.67B	$6.03	12.61
Jazz Pharmaceuticals	$4.27B	3.80	-$356.15M	-$0.02	N/A

Zoetis presently has a consensus target price of $118.33, suggesting a potential upside of 55.62%. Jazz Pharmaceuticals has a consensus target price of $259.06, suggesting a potential upside of 0.26%. Given Zoetis' higher possible upside, research analysts plainly believe Zoetis is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	1 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.41
Jazz Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.90

Zoetis has a net margin of 27.80% compared to Jazz Pharmaceuticals' net margin of 0.66%. Zoetis' return on equity of 66.85% beat Jazz Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.80%	66.85%	18.79%
Jazz Pharmaceuticals	0.66%	14.56%	5.25%

In the previous week, Zoetis had 16 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 36 mentions for Zoetis and 20 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.42 beat Zoetis' score of 1.13 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	29 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	17 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zoetis beats Jazz Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

Corcept Therapeutics has higher earnings, but lower revenue than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	16.68	$99.65M	$0.35	338.06
Jazz Pharmaceuticals	$4.27B	3.80	-$356.15M	-$0.02	N/A

93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Corcept Therapeutics has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market.

In the previous week, Corcept Therapeutics had 13 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 33 mentions for Corcept Therapeutics and 20 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.42 beat Corcept Therapeutics' score of 0.72 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	12 Very Positive mention(s)	3 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	17 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corcept Therapeutics currently has a consensus target price of $119.17, indicating a potential upside of 0.72%. Jazz Pharmaceuticals has a consensus target price of $259.06, indicating a potential upside of 0.26%. Given Corcept Therapeutics' higher probable upside, analysts clearly believe Corcept Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Jazz Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.90

Corcept Therapeutics has a net margin of 6.52% compared to Jazz Pharmaceuticals' net margin of 0.66%. Jazz Pharmaceuticals' return on equity of 14.56% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.52%	8.48%	6.57%
Jazz Pharmaceuticals	0.66%	14.56%	5.25%

Summary

Corcept Therapeutics beats Jazz Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Supernus Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 4.1% of Jazz Pharmaceuticals shares are held by insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Supernus Pharmaceuticals has lower revenue, but higher earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.80	-$356.15M	-$0.02	N/A
Supernus Pharmaceuticals	$718.95M	3.68	-$38.55M	-$0.51	N/A

In the previous week, Jazz Pharmaceuticals had 8 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 20 mentions for Jazz Pharmaceuticals and 12 mentions for Supernus Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.42 beat Supernus Pharmaceuticals' score of 0.99 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	17 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Supernus Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Jazz Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

Jazz Pharmaceuticals has a net margin of 0.66% compared to Supernus Pharmaceuticals' net margin of -3.74%. Jazz Pharmaceuticals' return on equity of 14.56% beat Supernus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	0.66%	14.56%	5.25%
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%

Jazz Pharmaceuticals presently has a consensus target price of $259.06, suggesting a potential upside of 0.26%. Supernus Pharmaceuticals has a consensus target price of $62.83, suggesting a potential upside of 37.76%. Given Supernus Pharmaceuticals' higher probable upside, analysts plainly believe Supernus Pharmaceuticals is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.90
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Jazz Pharmaceuticals beats Supernus Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

Get Jazz Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JAZZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JAZZ vs. The Competition

Export

Metric	Jazz Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$16.08B	$3.71B	$7.04B	$12.02B
Dividend Yield	N/A	2.13%	2.65%	10.11%
P/E Ratio	-12,912.54	23.35	27.69	23.57
Price / Sales	3.80	182.28	488.19	77.65
Price / Cash	15.74	165.25	51.74	58.30
Price / Book	3.64	8.05	10.04	5.85
Net Income	-$356.15M	$23.81M	$3.60B	$336.53M
7 Day Performance	1.78%	0.21%	0.66%	0.35%
1 Month Performance	7.22%	-6.22%	-3.29%	-4.99%
1 Year Performance	125.40%	41.74%	24.47%	17.95%

Jazz Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JAZZ Jazz Pharmaceuticals	2.2728 of 5 stars	$258.38 +0.9%	$259.06 +0.3%	+122.5%	$16.08B	$4.27B	N/A	2,890	Positive News Upcoming Earnings
AXSM Axsome Therapeutics	3.0124 of 5 stars	$221.64 -3.6%	$259.05 +16.9%	+131.7%	$11.84B	$638.50M	N/A	380	Positive News
RPRX Royalty Pharma	3.5471 of 5 stars	$57.29 -1.5%	$56.57 -1.3%	+59.0%	$33.50B	$2.38B	38.97	80	Positive News Upcoming Earnings
ZTS Zoetis	4.9667 of 5 stars	$76.17 -0.5%	$120.83 +58.6%	-48.9%	$32.10B	$9.47B	12.63	14,500	Positive News Upcoming Earnings
CORT Corcept Therapeutics	2.2269 of 5 stars	$91.57 +1.2%	$88.83 -3.0%	+69.2%	$9.72B	$761.41M	261.64	300	Trending News Earnings Report Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JAZZ) was last updated on 7/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jazz Pharmaceuticals (JAZZ) Competitors

JAZZ vs. AXSM, RPRX, ZTS, CORT, and SUPN

How does Jazz Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Jazz Pharmaceuticals compare to Royalty Pharma?

Summary

How does Jazz Pharmaceuticals compare to Zoetis?

Summary

How does Jazz Pharmaceuticals compare to Corcept Therapeutics?

Summary

How does Jazz Pharmaceuticals compare to Supernus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAZZ vs. The Competition

Jazz Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jazz Pharmaceuticals (JAZZ) Competitors

JAZZ vs. AXSM, RPRX, ZTS, CORT, and SUPN

How does Jazz Pharmaceuticals compare to Axsome Therapeutics?

Is JAZZ or AXSM more profitable?

Do analysts rate JAZZ or AXSM?

Does the media favor JAZZ or AXSM?

Which has more volatility & risk, JAZZ or AXSM?

Do institutionals and insiders have more ownership in JAZZ or AXSM?

Which has better earnings & valuation, JAZZ or AXSM?

Summary

How does Jazz Pharmaceuticals compare to Royalty Pharma?

Which has more volatility & risk, JAZZ or RPRX?

Which has higher earnings & valuation, JAZZ or RPRX?

Do analysts rate JAZZ or RPRX?

Do institutionals and insiders have more ownership in JAZZ or RPRX?

Is JAZZ or RPRX more profitable?

Does the media prefer JAZZ or RPRX?

Summary

How does Jazz Pharmaceuticals compare to Zoetis?

Do insiders & institutionals have more ownership in ZTS or JAZZ?

Which has more risk and volatility, ZTS or JAZZ?

Which has preferable earnings & valuation, ZTS or JAZZ?

Do analysts prefer ZTS or JAZZ?

Is ZTS or JAZZ more profitable?

Does the media prefer ZTS or JAZZ?

Summary

How does Jazz Pharmaceuticals compare to Corcept Therapeutics?

Which has better earnings & valuation, CORT or JAZZ?

Do insiders & institutionals have more ownership in CORT or JAZZ?

Which has more risk and volatility, CORT or JAZZ?

Does the media refer more to CORT or JAZZ?

Do analysts recommend CORT or JAZZ?

Is CORT or JAZZ more profitable?

Summary

How does Jazz Pharmaceuticals compare to Supernus Pharmaceuticals?

Do institutionals and insiders have more ownership in JAZZ or SUPN?

Which has stronger valuation and earnings, JAZZ or SUPN?

Does the media favor JAZZ or SUPN?

Which has more volatility and risk, JAZZ or SUPN?

Is JAZZ or SUPN more profitable?

Do analysts prefer JAZZ or SUPN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAZZ vs. The Competition

Jazz Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools